Neoplasm Recurrence, Local
"Neoplasm Recurrence, Local" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
| Descriptor ID |
D009364
|
| MeSH Number(s) |
C04.697.655 C23.550.727.655
|
| Concept/Terms |
Neoplasm Recurrence, Local- Neoplasm Recurrence, Local
- Local Neoplasm Recurrences
- Locoregional Neoplasm Recurrence
- Recurrences, Local Neoplasm
- Neoplasm Recurrences, Local
- Recurrence, Local Neoplasm
- Recurrence, Locoregional Neoplasm
- Local Neoplasm Recurrence
- Neoplasm Recurrence, Locoregional
- Locoregional Neoplasm Recurrences
- Neoplasm Recurrences, Locoregional
- Recurrences, Locoregional Neoplasm
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Recurrence, Local".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Recurrence, Local".
This graph shows the total number of publications written about "Neoplasm Recurrence, Local" by people in this website by year, and whether "Neoplasm Recurrence, Local" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 10 | 27 | 37 |
| 1995 | 17 | 29 | 46 |
| 1996 | 20 | 38 | 58 |
| 1997 | 14 | 31 | 45 |
| 1998 | 16 | 43 | 59 |
| 1999 | 23 | 29 | 52 |
| 2000 | 21 | 38 | 59 |
| 2001 | 26 | 57 | 83 |
| 2002 | 40 | 38 | 78 |
| 2003 | 55 | 45 | 100 |
| 2004 | 57 | 51 | 108 |
| 2005 | 55 | 66 | 121 |
| 2006 | 60 | 64 | 124 |
| 2007 | 63 | 69 | 132 |
| 2008 | 67 | 60 | 127 |
| 2009 | 44 | 85 | 129 |
| 2010 | 71 | 83 | 154 |
| 2011 | 75 | 78 | 153 |
| 2012 | 87 | 48 | 135 |
| 2013 | 83 | 93 | 176 |
| 2014 | 109 | 69 | 178 |
| 2015 | 116 | 89 | 205 |
| 2016 | 110 | 54 | 164 |
| 2017 | 112 | 79 | 191 |
| 2018 | 112 | 84 | 196 |
| 2019 | 97 | 81 | 178 |
| 2020 | 105 | 119 | 224 |
| 2021 | 67 | 158 | 225 |
| 2022 | 14 | 164 | 178 |
| 2023 | 11 | 160 | 171 |
| 2024 | 47 | 61 | 108 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm Recurrence, Local" by people in Profiles.
-
Real-world use of immune checkpoint inhibitors in advanced or recurrent endometrial cancer. Int J Gynecol Cancer. 2024 Nov 04; 34(11):1719-1728.
-
A Phase 1 Study of ABI-009 (Nab-sirolimus) in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors-A Children's Oncology Group Pediatric Early Phase Clinical Trial Network Study ADVL1514. Cancer Med. 2024 Nov; 13(21):e70376.
-
A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies. Clin Cancer Res. 2024 Nov 01; 30(21):4844-4855.
-
Body composition in recurrent prostate cancer and the role of steroidogenic genotype. Endocr Relat Cancer. 2024 Dec 01; 31(12).
-
Multiomic and clinical analysis of multiply recurrent meningiomas reveals risk factors, underlying biology, and insights into evolution. Sci Adv. 2024 Oct 25; 10(43):eadn4419.
-
Optimised treatment of patients with enlarged lateral lymph nodes in rectal cancer: protocol of an international, multicentre, prospective registration study after extensive multidisciplinary training (LaNoReC). BMJ Open. 2024 Oct 16; 14(10):e083225.
-
Real-World Implications of the SOUND Trial. Ann Surg Oncol. 2024 Dec; 31(13):8776-8785.
-
SDHB-Associated Pheochromocytomas: What is Their Clinical Behavior? Ann Surg Oncol. 2024 Dec; 31(13):9007-9013.
-
Can We Offset Local Recurrence in Locally Advanced Non-Small Cell Lung Cancer? The Merry-Go-Round of Radiation Dose Escalation and Stubborn Outcomes. J Clin Oncol. 2024 Nov 20; 42(33):3895-3900.
-
Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early-Stage Malignant Melanoma. Cancer Med. 2024 Oct; 13(19):e70313.